Description
Prevención de eventos esqueléticos en pacientes con metástasis óseas por tumores sólidos
PRINCIPIO ACTIVO: ENOXAPARINA SODICA 20 MG
PRINCIPIO ACTIVO: FEXOFENADINA
SUSTANCIA: DAFLOXEN F SUPOS
Suspensión
ZYMAR XD 0 5% SOL 2 5ML CLONIXINATO DE LISINA Prevención de eventos esqueléticos enPRINCIPIO ACTIVO: GATIFLOXACINO (OFTALMICO) 0. 005 DOSIS: 1. 5 ML FORMA FARMACUTICA: 1 SOLUCION PRESENTACIN: 1 CAJA
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
You may also like
recommand products
